P/E ratio for Horizon Therapeutics (HZNP)
P/E ratio as of April 2024 (TTM): 60.6
According to Horizon Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 60.5729. At the end of 2022 the company had a P/E ratio of 49.9.
P/E ratio history for Horizon Therapeutics from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 49.9 | 8.85% |
| 2021 | 45.9 | 9.7% |
| 2020 | 41.8 | 251.03% |
| 2019 | 11.9 | -120.11% |
| 2018 | -59.2 | 922.02% |
| 2017 | -5.79 | -62.76% |
| 2016 | -15.6 | -115.79% |
| 2015 | 98.5 | -2919.74% |
| 2014 | -3.49 | 7.27% |
| 2013 | -3.26 | 253.59% |
| 2012 | -0.9209 | 317.17% |
| 2011 | -0.2208 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 14.2 | -76.64% | 🇺🇸 USA |
 Amgen AMGN | 19.3 | -68.09% | 🇺🇸 USA |
 Merck MRK | 69.7 | 14.99% | 🇺🇸 USA |
 AstraZeneca AZN | 35.7 | -41.07% | 🇬🇧 UK |
 Dr. Reddy's RDY | 19.3 | -68.20% | 🇮🇳 India |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.